RxDoctor Payments Data

H Morris, MD

Glaucoma Specialist · Ocala, FLNPI 1275525057

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,136 of the $3,099 with a category attached, or 68.9%. Alcon accounts for 65.8% of it on its own, with 5 other manufacturers making up the rest. That places this record below the midpoint for glaucoma specialist clinicians in FL, where the typical reported total is $4,128.

$3,099in general payments, 2019–2025

Across 78 payments — averaging $39.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • AbbVie$857
  • Rxsight Inc$128
  • Rayner Intraocular Lenses Limited$37
  • Dompe US, Inc.$23
  • Aerie Pharmaceuticals, Inc.$15

What the payments were for

  • Travel & lodging$96331%
  • Food & beverage$2,13669%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,099 in reported general payments places this provider in the 35th percentile of 31 glaucoma specialist providers in Florida.

See all glaucoma specialist providers in Florida

Medicare billing

Part B allowed, 2024
$495,209
Medicare patients
1,365
Services billed
4,124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost280$156,526
CombiganBrimonidine Tartrate/Timolol91$63,234
RestasisCyclosporine29$39,638
Alphagan PBrimonidine Tartrate42$25,272
Travoprost85$19,800
RhopressaNetarsudil Mesylate23$16,941
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol92$16,055
VyzultaLatanoprostene Bunod41$15,798
Latanoprost998$13,999
SimbrinzaBrinzolamide/Brimonidine Tart23$12,054
Brinzolamide40$9,193
ProlensaBromfenac Sodium26$9,015
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat428$8,987
Prednisolone Acetate242$8,170
Cyclosporine18$7,786

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis, Alphagan P$857$284,670442 claims
Aerie Pharmaceuticals, Inc.Rhopressa$15$16,94123 claims
AlconSimbrinza$2,039$12,05423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 31 glaucoma specialist providers in Florida.

Other glaucoma specialist in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →